Drug-GPT

From shifting drug forecasts to early-stage breakthroughs, we've compiled the latest updates shaping the pharma and biotech landscape this week. ?? Bayer’s Xarelto dwindle?- Bayer has updated its pharmaceutical sales forecast for 2025, forecasting a 1% to 4% decline in sales, primarily due to the faster-than-expected generic competition for its blockbuster drug, Xarelto. There has been a reported 14.7% drop in Xarelto sales in 2024, with expectations of worse performance this year. Despite the ongoing challenges, Bayer’s CEO remains optimistic about long-term recovery, predicting an increase in 2027. https://lnkd.in/dWi9bWxj ?? Persica’s cLBP?treatment?- Persica Pharmaceuticals announced promising early-stage results for its antibiotic-based therapy, PP353, aimed at chronic low back pain (cLBP). The trial showed significant pain reduction and improvements in disability for patients who didn’t respond to other treatments. The intradiscal antibiotic therapy, showed its potential as an effective option for this patient population. https://lnkd.in/etR-YwaX ?? Asceneuron discontinues Alzheimer study?- Asceneuron has discontinued its Phase II trial of ASN5, an O-GlcNAcase inhibitor for Alzheimer’s, calling it a “strategic decision”. Irrespective of this decision, the company continues its focus on tau-related diseases, including ASN90 for progressive supranuclear palsy, and potential for preventing protein aggregation in diseases like Parkinson’s and amyotrophic lateral sclerosis. https://lnkd.in/eBVBBTGy ?? IN8bio moves to Autoimmunity?- IN8bio is shifting gears to focus on gamma-delta T cell engager platform, led by INB-619, a CD19-targeted TCE that could help treat leukaemias, lymphomas and autoimmune diseases. This approach aims to provide off-the-shelf treatments with fewer side effects compared to traditional therapies. https://lnkd.in/erWBYawr ??Acelyrin merger status?-Acelyrin has rejected an unsolicited acquisition bid from Concentra and will proceed with a merger with Alumis, as planned. The combined entity will focus on immune-mediated diseases, with enough funding to support clinical trials through 2027.https://https://lnkd.in/eTpBxriq ?? Want to understand what these mean for your Pharma Marketing plans? Let’s talk - https://lnkd.in/eA8_P74h #MedicineTrends #HealthcareMarketing #AI

After a packed week of innovation, announcements, and AI in action, our Data Intelligence & Analytics lead Roma English Owen highlights three standout trends from GTC 2025 with focusing on what they could mean for Healthcare and Life Sciences.? #GTC2025 #AIinAction #AdvancedDataScience #HealthcareInnovation

Don't miss out on some fantastic insights from the #NVIDIAGTC AI Conference happening this week in San Jose! Follow Roma English Owen, our Data Intelligence & Analytics Lead, as she shares the latest AI trends and innovations straight from the event. ?? #AI #HealthcareMarketing

?? Big Shifts Ahead: The Top 10 Drugs Losing Exclusivity in 2025 ?? With key blockbuster drugs set to lose their market exclusivity in 2025, the pharma landscape is gearing up for major changes. What does this mean for market access, competitive pricing, and brand strategy? ?? Expect increased competition from generics and biosimilars. ?? Pharma marketers will need to adapt their strategies for sustained brand value. Read the full list of drugs losing exclusivity and what it means for the industry: https://hubs.la/Q03c4Gpm0 #PharmaMarketing #DrugExclusivity #MarketAccess

The EU AI Act is here—the world’s first comprehensive AI regulation. With key provisions already in effect and full enforcement coming in 2026, businesses must start preparing now. To support AI adoption and compliance, the AI Pact provides guidance, shared best practices, and a platform for businesses to collaborate on responsible AI use. Read our latest blog to understand the AI Act, the AI Pact, and what it means for businesses across Europe. ?? Read more: https://hubs.la/Q03bKtcf0 #AIAct #AIPact #AIRegulation #HealthcareAI #Compliance #Innovation

From tracking industry conversations to refining messaging strategies, Advanced Data Science and AI helps Strategists stay ahead by uncovering trends, analyzing competitor positioning, and identifying key HCP insights. Want to know how AI can sharpen your competitive edge? Swipe through to learn more. ?? #PharmaMarketing #AIinPharma #CompetitiveIntelligence

With a fragmented media landscape, Pharma brands risk blending into the noise. The path forward? Leveraging unstructured data for deeper audience understanding, refining creative for more aligned messaging, and breaking the mold with fresh, engaging content. Advanced Data Science and AI can help marketers do just that—transforming unstructured conversational data from HCPs and Patients into data-driven intelligence that fuels smarter strategies. Read more from Fierce Pharma in their recent article: ??https://hubs.la/Q03bvdLx0 Get in touch if you’d like to discuss how Advanced Data Science and AI can enhance your Pharma Marketing ?? https://hubs.la/Q03bvpmK0 #AIinMarketing #PharmaMarketing #HealthcareAI #AudienceIntelligence

This International Women’s Day, we’re shining a light on some of the incredible women at Talking Medicines who are shaping the future of AI, Data Science, and Healthcare Marketing. Women remain underrepresented in STEM, yet their contributions are driving meaningful change—something we see every day in our own team. From leading AI advancements to translating complex data into actionable insights, their work is at the heart of what we do. At Talking Medicines, we’re committed to fostering an inclusive environment where female talent thrives. Read more about how we champion women in STEM and celebrate the expertise that fuels our success: ?? https://hubs.la/Q039J6B_0 Britteny Gibson Erin Macfarlane Roma English Owen Jo Halliday Elizabeth Fairley Ellie Halliday Kirsty Mursec Aishwarya Raman #InternationalWomensDay #IWD2025 #WomenInSTEM #AI #DataScience #HealthcareMarketing

What trends are you keeping an eye on???? Our COO & CDO, Elizabeth Fairley, shares the top five Pharma and medicine trends to watch right now. From groundbreaking treatment advancements to shifting regulatory landscapes. Check out her insights below. ???Drop your thoughts in the comments!?What stands out to you?

AI is here, but are we using it the right way? 80% of Pharma Marketers are leveraging AI, yet its real value comes when paired with human insight. For Marketers, the question isn’t if AI fits into their marketing plans—it’s how to make it work smarter. Let’s break it down ???https://lnkd.in/gm49Ejb2 #AIinPharmaMarketing #PatientIntelligence #HCPIntelligence